Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 22, 2024
Product Development
Clinical Report: GSK records asthma win
Plus: Data from Amgen-AstraZeneca, Biogen-Ionis and more
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Feb 7, 2024
Product Development
Innate immunity gets another shot at cancer through ADCs
Immunostimulatory antibody-drug conjugates move from concept to clinical product
BioCentury | Dec 23, 2023
Discovery & Translation
Taking next-gen mAbs to new heights will lead modality innovation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey
BioCentury | Apr 19, 2023
Data Byte
ADCs overtake mAbs in AACR’s first-in-human abstracts
BioCentury’s analysis of 25 first-in-human studies presented at AACR 2023
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
BioCentury | Nov 5, 2022
Discovery & Translation
A gene therapy to drive hyperexcitable neurons back to baseline; plus a conditionally active IL-2 and more
BioCentury’s roundup of translational news
BioCentury | Aug 9, 2022
Deals
Mersana-GSK deal adds to immunostimulatory ADC momentum
The preclinical HER2-targeted ADC with a STING agonist payload is netting Mersana $100M up front and a path to co-commercialization
Items per page:
1 - 10 of 259